Cancer pain

DGAP-News: Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF(TM)

Thursday, October 14, 2021 - 2:29pm

Since the beginning of the clinical development program in late-2016, QIXLEEF(TM) strictly adhered to and complied with the regulatory requirements of a prescription drug.

Key Points: 
  • Since the beginning of the clinical development program in late-2016, QIXLEEF(TM) strictly adhered to and complied with the regulatory requirements of a prescription drug.
  • Having a global drug development strategy ensures economy of scale and lower cost of drug development to shareholders.
  • The REBORN(c) clinical strategy provides the fastest and lowest cost development program to bring QIXLEEF(TM) to the market.
  • Guy Chamberland, CEO and CRO commented, "Our team has made significant progress in bringing QIXLEEF(TM) to a late clinical development stage.

Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™

Thursday, October 14, 2021 - 11:30am

Since the beginning of the clinical development program in late-2016, QIXLEEF strictly adhered to and complied with the regulatory requirements of a prescription drug.

Key Points: 
  • Since the beginning of the clinical development program in late-2016, QIXLEEF strictly adhered to and complied with the regulatory requirements of a prescription drug.
  • The Company completed two Phase 1 clinical trials in healthy volunteers to assess the safety profile, including cardiovascular, pharmacodynamics and pharmacokinetics, of smoked and vaporized QIXLEEF.
  • The REBORN clinical strategy provides the fastest and lowest cost development program to bring QIXLEEF to the market.
  • Guy Chamberland, CEO and CRO commented, "Our team has made significant progress in bringing QIXLEEF to a late clinical development stage.

Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021

Thursday, September 2, 2021 - 2:00pm

Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ:VRPX), today announced it will present a poster on Leucine Enkephalin as a potential analgesic at PAINWeek 2021, being held on September 7-11, 2021 at The Cosmopolitan in Las Vegas, NV.

Key Points: 
  • Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ:VRPX), today announced it will present a poster on Leucine Enkephalin as a potential analgesic at PAINWeek 2021, being held on September 7-11, 2021 at The Cosmopolitan in Las Vegas, NV.
  • The following poster from Virpax will be presented on Thursday, September 9th from 6:30 p.m. 8:30 p.m. PST:
    Drug overdose deaths in the U.S. rose nearly 30% in 2020.
  • I am delighted to serve as principal investigator for this promising molecule with multiple actions in the central and peripheral nervous system.
  • Envelta is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.

National Cancer Research Institute endorses CBD Science Group as they pioneer Real World research into Cancer pain

Thursday, September 2, 2021 - 12:00am

LONDON, Sept. 2, 2021 /PRNewswire/ -- CBD Science Group (the 'Company') is delighted to announce a highly sought-after endorsement from the National Cancer Research Institute (NCRI), which has seen the NCRI Living With and Beyond Cancer (LWBC) Executive Group endorse the company's Real World Evidence (RWE) study into the role that cannabinoids can play in treating cancer related pain. The development will give hope to cancer patients world wide as the treatment and management of cancer pain continues to be a major burden on patients and families.

Key Points: 
  • The development will give hope to cancer patients world wide as the treatment and management of cancer pain continues to be a major burden on patients and families.
  • CBD Science Group is a biopharmaceutical company who are enabling accelerated access to treatment through a pragmatic Real World Evidence, peer-reviewed clinical trial.
  • This partnership will further progress CBD Science Group towards our objective of realising the advantages of cannabinoids in fulfilling this urgent need of suffering patients.
  • CBD Science Group undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of CBD Science Group, its securities, or financial or operating results (as applicable).

National Cancer Research Institute endorses CBD Science Group as they pioneer Real World research into Cancer pain

Thursday, September 2, 2021 - 12:00am

LONDON, Sept. 2, 2021 /PRNewswire/ -- CBD Science Group (the 'Company') is delighted to announce a highly sought-after endorsement from the National Cancer Research Institute (NCRI), which has seen the NCRI Living With and Beyond Cancer (LWBC) Executive Group endorse the company's Real World Evidence (RWE) study into the role that cannabinoids can play in treating cancer related pain. The development will give hope to cancer patients world wide as the treatment and management of cancer pain continues to be a major burden on patients and families.

Key Points: 
  • CBD Science Group is delighted to confirm that it's Real World Evidence (RWE) Study has been endorsed by the National Cancer Research Institute (NCRI) Living With and Beyond Cancer (LWBC) Executive Group.
  • LONDON, Sept. 2, 2021 /PRNewswire/ --CBD Science Group (the 'Company') is delighted to announce a highly sought-after endorsement from the National Cancer Research Institute (NCRI), which has seen the NCRI Living With and Beyond Cancer (LWBC) Executive Group endorse the company's Real World Evidence (RWE) study into the role that cannabinoids can play in treating cancer related pain.
  • The development will give hope to cancer patients world wide as the treatment and management of cancer pain continues to be a major burden on patients and families.
  • CBD Science Group is a biopharmaceutical company who are enabling accelerated access to treatment through a pragmatic Real World Evidence, peer-reviewed clinical trial.

Dr. Trey Mouch Joins Central Texas Pain Center in Austin and Bee Cave

Thursday, July 29, 2021 - 12:00pm

AUSTIN, Texas, July 29, 2021 /PRNewswire/ --Central Texas Pain Center is pleased to announce that Dr. Trey Mouch has joined the Central Texas Pain Center team after finishing his interventional pain fellowship at Weill Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Hospital for Special Surgery in New York.Dr.

Key Points: 
  • AUSTIN, Texas, July 29, 2021 /PRNewswire/ --Central Texas Pain Center is pleased to announce that Dr. Trey Mouch has joined the Central Texas Pain Center team after finishing his interventional pain fellowship at Weill Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Hospital for Special Surgery in New York.Dr.
  • Mouch will be providing patient care for Central Texas Pain Center in the rapidly growing Central and South Austin and Bee Cave neighborhoods of Austin, TX.
  • A native of Dallas, Texas, Dr. Mouch completed medical school at the University of Texas Health Science Center San Antonio.He has special interests in cancer pain, peripheral nerve therapies, and minimally invasive spinal therapy, including spinal cord stimulation and spinal decompression Therapies.
  • In addition, he firmly believes in a personalized and multidisciplinary approach to pain management to reduce patients' level of pain and increase their quality of life.

Q-State Biosciences Awarded NIH Grant for the Development of ASO Therapies Targeting Cancer Pain

Tuesday, July 20, 2021 - 10:00pm

Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the development of antisense oligonucleotide (ASO) therapeutics for the treatment of cancer pain. Q-State will subsequently be eligible for an additional $1 million in grant funding based on successful completion of certain program milestones.

Key Points: 
  • Funded as part of the NIH HEAL InitiativeSM, the grant supports Q-States efforts to pursue analgesic treatment paradigms beyond those associated with opioids.
  • The company is currently advancing ASO candidates targeting Nav1.7, Nav1.8, or both channels using the companys AI-enabled computational neuroscience technology.
  • In addition to cancer pain, these ASO candidates also have potential applicability in the treatment of a variety of other moderate-to-severe pain states.
  • This grant was awarded by the National Institute of Cancer of the National Institutes of Health under Award Number R44CA247110.

Worldwide Pain Therapeutics Industry to 2030 - More Advanced Molecular and Biological Techniques are Improving the Understanding of Pain

Tuesday, April 20, 2021 - 2:30pm

Major segments of the pain market are arthritis, neuropathic pain and cancer pain.

Key Points: 
  • Major segments of the pain market are arthritis, neuropathic pain and cancer pain.
  • Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery.
  • Various cell and gene therapies are also being developed for the management of pain.\nAdvances in molecular and biological techniques are markedly advancing our understanding of pain.
  • Understanding the pathophysiology of pain is an important factor in the discovery of rational therapies for pain.

Global Pain Therapeutics Market Report 2021 - Profiling 173 Companies Along with 156 Collaborators - ResearchAndMarkets.com

Thursday, April 15, 2021 - 12:46pm

b'The "Pain Therapeutics - Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThis report describes the latest concepts of pathomechanisms of pain as a basis for the management and development of new pharmacotherapies for pain.

Key Points: 
  • b'The "Pain Therapeutics - Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThis report describes the latest concepts of pathomechanisms of pain as a basis for the management and development of new pharmacotherapies for pain.
  • Major segments of the pain market are arthritis, neuropathic pain and cancer pain.
  • Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery.
  • The report is supplemented with 77 tables, 25 figures, and 600 selected references to the literature.\nThe report contains information on the following:\n'

United States Pain Management Drugs Market Opportunity Analysis and Industry Forecast, 2020-2027: $39.35 Billion Market by Drug Class, Indication, Pain Type - ResearchAndMarkets.com

Friday, April 2, 2021 - 10:25am

Pain Management Drugs Market by Drug Class, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Pain Management Drugs Market by Drug Class, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The length of the pain would range from acute pain for short term to chronic pain for long term.
  • The U.S. pain management drugs market is segmented on the basis of drug class, indication, pain type, and region.
  • On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis and others.